The ratio of free prostate-specific antigen (f-PSA) to total PSA (t-PSA) in serum, calculated as percent free PSA (f-PSA%), is lower in patients with prostate carcinoma (PCa) than in patients with benign prostate hyperplasia (BPH). This parameter facilitates discrimination between the 2 groups of pa
The ratio of free to total serum prostate specific antigen and its use in differential diagnosis of prostate carcinoma in japan
β Scribed by Shin Egawa; Shigehiro Soh; Makoto Ohori; Toyoaki Uchida; Kazuo Gohji; Akio Fujii; Sadahito Kuwao; Ken Koshiba
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 138 KB
- Volume
- 79
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
β¦ Synopsis
BACKGROUND.
To improve the clinical usefulness of prostate specific antigen (PSA),
π SIMILAR VOLUMES
T1, 2, 3pN0, M0), 44 patients with BPH, and 54 healthy Charite Β΄, Humboldt University Berlin, Berlin, Gercontrols. Prostate volume was determined by transrectal ultrasound. many. ## RESULTS. The median values of t-PSA and f-PSA% were 7.8 mg/L and 10.5% in PCa patients, 4.3 mg/L and 20.8% in patie
Background. Prostate specific antigen (PSA) is useful as a tumor marker for monitoring patients with prostate cancer after definitive therapy. Limitations have been noted when PSA was used for the early detection of prostate cancer. The use of prostate specific antigen density [PSAD = PSA (ng/ml)/pr
The volume of the transition zone was also measured by TRUS in 134 patients.
## BACKGROUND. Human glandular kallikrein (hK2), the prostate specific antigen (PSA) close homologue, possesses approximately 80% structure identity with PSA. The identification of PSA was an important step in the detection of prostate carcinoma (PCa). Thus, hK2 measurement in the serum has the po